Jianhong Long
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianhong Long has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Jiaguang Li
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China
2 shared publications- Shaorong Lei
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China
2 shared publications Wuyuan Tan
2 shared publicationsJingjing Zhang
Department of Plastic and Aesthetic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China
1 shared publicationMin Qi
1 shared publicationMuzhang Xiao
1 shared publication
Latest Publications
- 1 November 2015
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 26 (8) , e758-e761
Customized Titanium Mesh for Repairing Cranial Defects
Titanium cranioplasty is one of the well-established and widely used techniques for repairing cranial defects. In this paper, we present an improved way to design and create titanium meshes with more evaluation process. Computed tomography scan data of patients were used to create three-dimensional virtual models. Implants were designed with NX ImageWare 13.2 (Siemens PLM Software, Plano, TX). Final titanium meshes were assessed by Geomagic Studio 12 (Geomagic, Inc., Morrisville, NC) and NX ImageWare 13.2.Titanium meshes were designed and applied to cranioplasty surgery on 8 patients. Postoperative results were evaluated by computed tomography scanning and further analyzed with rainbow difference tomography. All patients were satisfied with the outcome. With this method, surgeons, engineers, and patients work together to evaluate and edit implant design. Our method provides better communication and comprehensive evaluation, which result in a satisfying outcome.
- 1 November 2015
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 26 (8) , e758-e761
Customized Titanium Mesh for Repairing Cranial Defects
Titanium cranioplasty is one of the well-established and widely used techniques for repairing cranial defects. In this paper, we present an improved way to design and create titanium meshes with more evaluation process. Computed tomography scan data of patients were used to create three-dimensional virtual models. Implants were designed with NX ImageWare 13.2 (Siemens PLM Software, Plano, TX). Final titanium meshes were assessed by Geomagic Studio 12 (Geomagic, Inc., Morrisville, NC) and NX ImageWare 13.2.Titanium meshes were designed and applied to cranioplasty surgery on 8 patients. Postoperative results were evaluated by computed tomography scanning and further analyzed with rainbow difference tomography. All patients were satisfied with the outcome. With this method, surgeons, engineers, and patients work together to evaluate and edit implant design. Our method provides better communication and comprehensive evaluation, which result in a satisfying outcome.
- 1 August 2015
- Vol. 40 (8)
[Endovascular treatment for venous malformations with three-point anhydrous ethanol injection].
To explore the safe method with anhydrous ethanol injection in the treatment of venous malformation.
- 1 August 2015
- Vol. 40 (8)
[Endovascular treatment for venous malformations with three-point anhydrous ethanol injection].
To explore the safe method with anhydrous ethanol injection in the treatment of venous malformation.
- 11 August 2014
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 10 (4) , 1845-1850
MacroH2A suppresses the proliferation of the B16 melanoma cell line
MacroH2A is the most frequently altered histone, which participates in cancer progression. Increasing evidence demonstrates that cancer progression could be regulated by macroH2A by affecting the cell cycle. In the present study, it was demonstrated that macroH2A suppresses melanoma cell progression and the molecular mechanisms underlying this process were examined. The interference and overexpression vectors of macroH2A were constructed and then transferred into B16 melanoma cells and, following transfection, were analyzed by quantitative polymerase chain reaction (PCR), western blot analysis and immunofluorescence assays. Apoptosis and the cell cycle stage among all the treatment groups were detected. Then, cyclin D1, cyclin D3, cyclin-dependent protein kinase (CDK) 4, CDK6 and CDK8 expression was detected in order to elucidate the effects of macroH2A on cell cycle-related genes. The results demonstrated that the overexpression of macroH2A suppressed melanoma cell progression and arrested the cells in the G2/M stage. Furthermore, macroH2A inhibits cyclin D1, cyclin D2, CDK6 and CDK8 expression in B16 melanoma cells. In conclusion, the results demonstrated that macroH2A, a critical component of chromatin, suppresses the development of melanoma (which results from a disordered cell cycle) through regulating cyclin D1, cyclin D3 and CDK6 genes.
- 11 August 2014
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 10 (4) , 1845-1850
MacroH2A suppresses the proliferation of the B16 melanoma cell line
MacroH2A is the most frequently altered histone, which participates in cancer progression. Increasing evidence demonstrates that cancer progression could be regulated by macroH2A by affecting the cell cycle. In the present study, it was demonstrated that macroH2A suppresses melanoma cell progression and the molecular mechanisms underlying this process were examined. The interference and overexpression vectors of macroH2A were constructed and then transferred into B16 melanoma cells and, following transfection, were analyzed by quantitative polymerase chain reaction (PCR), western blot analysis and immunofluorescence assays. Apoptosis and the cell cycle stage among all the treatment groups were detected. Then, cyclin D1, cyclin D3, cyclin-dependent protein kinase (CDK) 4, CDK6 and CDK8 expression was detected in order to elucidate the effects of macroH2A on cell cycle-related genes. The results demonstrated that the overexpression of macroH2A suppressed melanoma cell progression and arrested the cells in the G2/M stage. Furthermore, macroH2A inhibits cyclin D1, cyclin D2, CDK6 and CDK8 expression in B16 melanoma cells. In conclusion, the results demonstrated that macroH2A, a critical component of chromatin, suppresses the development of melanoma (which results from a disordered cell cycle) through regulating cyclin D1, cyclin D3 and CDK6 genes.